Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
This study was terminated on 16 Nov 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
BMI less or equal to 39 kg/m2
Osteoarthritis (arthritis) of the knee or hip with pain score that qualifies
Willing to comply with study visit schedule and study requirements, including, for women of child-bearing potential or male patients with female partners of child-bearing potential, the use of 2 forms of birth control, one of which is a barrier method.
Patients must consent in writing to participate in the study.
You may not be if
Untreated, uncontrolled diseases,
Unwilling or unable to discontinue the use of prohibited medications, including other pain medications, during the screening period and during the study,
Significant cardiac disease within the past 6 months
Significant neurological disease (e.g. peripheral neuropathy, multiple sclerosis, stroke) or signs of neuropathy at screening
Known bleeding disorder or anticoagulation therapy
Planned surgery during the study period
History of alcoholism or drug abuse in the past 2 years
Unable to use acetaminophen
Use of a biologic (including live vaccines, with the exception of Flumist) within the past 3 months
Allergic reaction to a biologic or an antibody in the past
Disqualifying laboratory values, including Hepatitis B or C, HIV or drug test
Cancer in the past 5 years. Basal cell or squamous cell carcinoma are okay.
Medical condition that may interfere with study endpoints or safety of the subject as determined by the investigator.
Clareo Health | Tanezumab and Nerve Function In Arthritis Patients
